Products for Research Use Only

Varenicline-d4

CAT: 0804-HY-10019SSize: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10019SSize:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Varenicline-d4 is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].
CAS Number
2183239-01-0
Product Name Alternative
CP 526555-d4
UNSPSC
12352005
Target
Isotope-Labeled Compounds; nAChR
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
[2H]C1([2H])NC([2H])([2H])C2CC1C3=CC4=NC=CN=C4C=C32
Molecular Formula
C13H9D4N3
Molecular Weight
215.29
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Bagdas D, et al. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.Neuropharmacology. 2018 Aug;138:72-79.|[3]Mihalak KB, et al. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.Mol Pharmacol. 2006 Sep;70 (3) :801-5. Epub 2006 Jun 9.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products